Insights

What’s going on with the Race Oncology (ASX:RAC) share price today?

Effective Leukemia treatment remains a serious therapeutic challenge.
The post What’s going on with the Race Oncology (ASX:RAC) share price today? appeared first on The Motley Fool Australia. –

The Race Oncology Ltd (ASX: RAC) share price is swinging from losses to gains to losses again. At time of writing, shares in the ASX healthcare company have slipped below yesterday’s closing price, trading down 0.29% at $3.38.

We take a look at Race Oncology’s Leukemia clinical trial update below.

What did Race announce?

The Race Oncology share price is seeking direction after the company reported the first patient has been dosed in its “Phase 1b/2 trial in relapsed/refractory Acute Myeloid Leukaemia” trial.

The trial will use the company’s Zantrene in a 3-drug combination. According to the release, this combination has demonstrated “compelling efficacy” in earlier pre-clinical studies. (See here for more.)

Professor Arnon Nagler of the Chaim Sheba Medical Center in Israel is leading the study. Nagler previously conducted the Phase 2 single agent Zantrene R/R AML trial, which demonstrated a 40% clinical response.

Acute Myeloid Leukemia (AML) remains difficult to effectively treat. According to the release, approximately “30% of adults with newly diagnosed AML fail to achieve complete remission (CR) after 2 courses of intensive chemotherapy”. For patients who do achieve CR following chemotherapy, 50% of younger and 80% of older patients relapse.

Even when CR is achieved through intense chemotherapy, approximately half of the younger and 80% of the older patients, relapse.

Race Oncology commentary

Commenting on the progress, Race’s chief medical officer David Fuller said:

We are delighted to see the start of this important clinical project which uses a novel combination approach for relapsed or refractory Acute Myleoid Leukaemia. This study is also an important step in our journey towards approval of Zantrene in this area of high unmet medical need.

Race’s CEO Phillip Lynch added, “We hope to see improved patient outcomes in what has been historically a difficult to treat disease. We plan on using our trademarked name, Zantrene, in referring to bisantrene dihydrochloride.”

The trial in Israel will run in parallel with an Australian Phase 2 trial in patients with extramedullary AML.

Race Oncology share price snapshot

Over the past 12 months the Race Oncology share price has gained 304%, well outpacing the 25% gains posted by the All Ordinaries Index (ASX: XAO) in that same time.

Year-to-date Race Oncology’s share price has continued to surge, up 82% in 2021.

The post What’s going on with the Race Oncology (ASX:RAC) share price today? appeared first on The Motley Fool Australia.

Should you invest $1,000 in Race Oncology right now?

Before you consider Race Oncology, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Race Oncology wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

More reading

Race Oncology (ASX:RAC) share price slumps on quarterly update

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!